
AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Jun 23
Feb 23
Innoplexus wins Horizon Interactive Gold Award for Curia App
Read MoreOntosightⓇ is a discovery platform that leverages proprietary artificial intelligence technologies to generate continuous insights for life sciences. OntosightⓇ Explore is a module of the platform that enables exploration, identification, and building of various direct and indirect connections between drugs, targets, pathways, and diseases.
Evidence-based network assists in the search of potential drugs and targets for a given disease. It helps in identification of strong and weak associations, prediction of potential drugs and targets for diseases of interest, and deep-diving to obtain granular scientific information to accelerate drug discovery along with significantly reduced time and cost spent on research and experimental studies.
OntosightⓇ Explore can be leveraged in the following ways:
Observe associations: Understand the interconnectedness of biological systems with regard to their search term, which can be a gene, target/protein, pathway, or disease.
Target validation: Identify all known pathways through which a given disease operates along with all of the proteins involved in those pathways which might present an opportunity for inhibition.
Drug repurposing: Identify closely associated therapeutic areas and their corresponding drugs, which might indicate that these drugs may be able to inhibit a common pathway between the two indications. Rank associations to prioritize assets based on their commonality/association, as well as their druggability and druglikeness.
Discover indirect/unknown connections: Easily find associations which are two degrees of separation away, which will help bypass the intermediary common entity to link a disease to a drug, a target to a drug, or a disease to a target directly.
OntosightⓇ Explore has data from 1M theses and dissertations, 35 M publications, 580 K clinical trials, 3 M congress articles, 20 M researchers & physicians, 6 K regulatory updates, 5 M grants etc. The tool also leverages associations between 300 K diseases, over 2 M chemical & drugs, 9 M genes and 500 K proteins etc.
Yes. Identification of novel targets in OntosightⓇ Explore is possible by searching for a particular disease or drug. Results can be filtered based on the “target classes” such as GPCR, Enzymes, Transporters etc. and based on the structure availability on Protein DataBank (PDB). Target prioritization can be done using druggability equalizer which leverages a number of parameters such as experimental structure of protein availability, number of antibody tasted, associated biomarkers, number of approved drugs, transmembrane helix etc. Moreover, one can view underlying documentation from publications, clinical trials, congresses, patents, etc. for validation of the association.
Yes. OntosightⓇ Explore helps to identify non-obvious connections which are basically those associations where there’s an opportunity to repurpose the drug for identified indication. The tool allows deep-dive into various underlying documentation from publications, clinical trials, congresses, patents, etc. to validate this association.
OntosightⓇ Explore connects data assets by tagging biomedical concepts, which are then normalized, disambiguated for most specific class or type of concepts and then connected together using Innoplexus’s proprietary self-learning biomedical ontology. This network consists of data aggregated from hundreds of public databases containing literature, biological pathway data, chemical information, gene data, clinical trials, patents, etc. that together create the holistic “knowledge graph.” These data sources are all updated in near real-time and represent the most up-to-date scientific understanding.
Whereas similar platforms can provide similar network visualizations of scientific knowledge, Innoplexus stands alone in its ability to correctly normalize / disambiguate concepts through our industry-leading self-learning life sciences ontology. This ensures that drugs associated with Colony Stimulating Factor (CSF) are not misassociated with Cerebral Spinal Fluid (CSF), for example, or that the diseases/targets/pathways associated with Lipitor and Atorvastatin are the same.
OntosightⓇ Explore is a subscription-based platform. If you are interested in identifying novel/potential targets for any given indication and drug, or in drug discovery, feel free to contact Innoplexus to set up a demo and quote.
The cost of developing a new drug roughly doubles every nine years (inflation-adjusted) aka Eroom’s law.As the volume of data…
There was a time when science depended on manual efforts by scientists and researchers. Then, came an avalanche of data…
Collaboration with key opinion leaders and influencers becomes crucial at various stages of the drug development chain. When a pharmaceutical…
Data are not the new gold – but the ability to put them together in a relevant and analyzable way…
Artificial intelligence, or AI, is gaining more attention in the pharma space these days. At one time evoking images from…
Artificial intelligence (AI) is transforming the pharmaceutical industry with extraordinary innovations that are automating processes at every stage of drug…
There is a lot of buzz these days about how artificial intelligence (AI) is going to disrupt the pharmaceutical industry….
Drug discovery plays a key role in the pharma and biotech industries. Discovering unmet needs, pinpointing the target, identifying the…
The pharmaceutical industry spends billions on R&D each year. Clinical trials require tremendous amounts of effort, from identifying sites and…
Training algorithms to identify and extract Life Sciences-specific data The English dictionary is full of words and definitions that can be…
The early 1970s introduced the world to the idea of computer vision, a promising technology automating tasks that would otherwise…
Summary:AI could potentially speed drug discovery and save time in rejecting treatments that are unlikely to yield worthwhile resultsAI has…